Nextgen (NXGN) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.111x

Based on the latest financial reports, Nextgen (NXGN) has a cash flow conversion efficiency ratio of 0.111x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.08 Million ≈ $-2.90K USD) by net assets (ILA-9.72 Million ≈ $-26.05K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Nextgen to measure how much of total assets are equity-financed.

Nextgen - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Nextgen's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore NXGN operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Nextgen Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nextgen ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
MUZHU MINING LTD
F:Y33
N/A
Severfield PLC
LSE:SFR
0.125x
Rights and Issues Investment Trust Public Limited Company
LSE:RIII
0.012x
Grupo Vasconia S.A.B
MX:VASCONI
0.006x
Margaret Lake Diamonds Inc
V:DIA
0.054x
Future Supply Chain Solutions Limited
NSE:FSC
0.108x
Diaceutics PLC
LSE:DXRX
0.021x
Ucommune International Ltd
NASDAQ:UK
-0.019x

Annual Cash Flow Conversion Efficiency for Nextgen (2013–2024)

The table below shows the annual cash flow conversion efficiency of Nextgen from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see NXGN market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ILA-2.46 Million
≈ $-6.61K
ILA-2.06 Million
≈ $-5.53K
0.837x -81.41%
2023-12-31 ILA-979.00K
≈ $-2.62K
ILA-4.41 Million
≈ $-11.81K
4.499x +2102.13%
2022-12-31 ILA12.25 Million
≈ $32.84K
ILA-2.75 Million
≈ $-7.38K
-0.225x -75.07%
2021-12-31 ILA20.71 Million
≈ $55.51K
ILA-2.66 Million
≈ $-7.13K
-0.128x +42.64%
2020-12-31 ILA6.87 Million
≈ $18.41K
ILA-1.54 Million
≈ $-4.12K
-0.224x +77.11%
2019-12-31 ILA1.17 Million
≈ $3.14K
ILA-1.15 Million
≈ $-3.07K
-0.978x -88.16%
2018-12-31 ILA2.39 Million
≈ $6.40K
ILA-1.24 Million
≈ $-3.33K
-0.520x -14.45%
2017-12-31 ILA3.66 Million
≈ $9.81K
ILA-1.66 Million
≈ $-4.45K
-0.454x -54.05%
2016-12-31 ILA5.13 Million
≈ $13.76K
ILA-1.51 Million
≈ $-4.06K
-0.295x +87.25%
2015-12-31 ILA1.74 Million
≈ $4.65K
ILA-4.01 Million
≈ $-10.76K
-2.312x -162.46%
2014-12-31 ILA-884.00K
≈ $-2.37K
ILA-3.27 Million
≈ $-8.77K
3.702x +205.08%
2013-12-31 ILA342.00K
≈ $916.89
ILA-1.21 Million
≈ $-3.23K
-3.523x --

About Nextgen

TA:NXGN Israel Medical Instruments & Supplies
Market Cap
$1.32 Million
ILA490.55 Million ILA
Market Cap Rank
#30378 Global
#449 in Israel
Share Price
ILA45.00
Change (1 day)
+17.19%
52-Week Range
ILA37.60 - ILA68.40
All Time High
ILA25020.00
About

Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.